TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22502814
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Helium Neon (He‐Ne) Laser therapy
Study: 11835024
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h)
Study: 11835024
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (bolus of 70 U/kg followed by an infusion of 15 U/kg/h)
Study: 11198951
Drug: High-dose supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supplements of nutrients (specific nutrients not detailed)
Study: 2036692
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% and fentanyl 4 micrograms.ml‐1 (Group I)
Study: 31122894
Drug: Eosinophil-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil-guided therapy (37.5 mg of oral prednisolone daily for up to 4 days based on eosinophil count)
Study: 31122894
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (37.5 mg of oral prednisolone daily for 4 days)
Study: 31122894
Drug: Eosinophil-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil-guided therapy
Study: 26218727
Drug: VYC‐20L (Juvéderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC‐20L (Juvéderm Voluma XC) with higher injection volumes
Study: 26218727
Drug: VYC‐20L (Juvéderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC‐20L (Juvéderm Voluma XC) with median injection volume of ≈2.0 mL
Study: 23967286
Drug: 40 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/d polyphenol soy protein complex (PSPC) for 17 days
Study: 19625744
Drug: Insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1 mU.kg(‐1).min(‐1)) and dextrose to maintain euglycemia
Study: 19625744
Drug: Insulin, dextrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin, dextrose, and octreotide
Study: 17355547
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy according to classical Chinese Medicine (Heidelberg Model)
Study: 11229246
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (ABD), 1 mg/kg day on days 1‐20, infusion completed in 2 hours.
Study: 11229246
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose of ABD (0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg on days 1‐5, then same dosage on alternate days), infusion completed in 6 hours.
Study: 7566302
Drug: Activated powdered
Normalized name: collagen,activated Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated powdered charcoal (6 g daily p.o.)
Study: 2231839
Drug: Maloprim (pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maloprim (pyrimethamine and dapsone) administered fortnightly by village health workers (VHWs)
Study: 688736
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg spironolactone per day (low dose)
Study: 688736
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg spironolactone per day (high dose)
Study: 21122419
Drug: NP/GP scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP/GP scheme synchronization chemotherapy combined with (125)I seed implantation brachytherapy
Study: 21122419
Drug: NP/GP scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP/GP scheme chemotherapy
Study: 15717462
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg x kg(‐1) bolus before incision, followed by continuous infusion of 1 mg x kg(‐1) x hr(‐1) during surgery)
Study: 15717462
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ketamine administration)
Study: 12501020
Drug: Injection activity
Normalized name: eptacog alfa activated Injection [Novoseven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection activity adjustment
Study: 8877156
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine (15 mg twice daily for 3 days)
Study: 8877156
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (single dose 10 min prior to allergen challenge)
Study: 31188064
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ADC ratio and ER
Study: 23944632
Drug: Statins (Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (Atorvastatin and Rosuvastatin)
Study: 16461248
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 2 mL tea catechin extract solution (3.7 mg/mL catechins, 43% epigallocatechin gallate) 3 times daily for 7 days
Study: 1547962
Drug: tobramycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h
Study: 1547962
Drug: tobramycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: tobramycin (15 mg/ml) in saline applied at 1 drop/h
Study: 3873582
Drug: Oxygenated crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenated crystalloid solution
Study: 3873582
Drug: Oxygenated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenated solution
Study: 30612946
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg once daily for 6 months
Study: 30612946
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone (about 1 mg/kg bodyweight) intramuscular injections every 4 weeks for 6 months
Study: 21490523
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (0.25% levobupivacaine and 30 μg/kg morphine)
Study: 21490523
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (0.5% levobupivacaine and 30 μg/kg morphine)
Study: 19679747
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (1 g/day for 7-16 days)
Study: 15010071
Drug: Chemotherapy patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy patients
Study: 15010071
Drug: Chemotherapy patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy patients with elevated PAI-1
Study: 9670603
Drug: CARL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARL therapy program (computerized exposure therapy)
Study: 7873699
Drug: CS+ (sherbet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS+ (sherbet sweet/white noise) paired with epinephrine injection (0.2 mg subcutaneously)
Study: 28164268
Drug: Supraclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraclavicular block with 20 ml of 0.375% ropivacaine
Study: 28164268
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block with 20 ml of 0.375% ropivacaine
Study: 22556209
Drug: Daily feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily feeding supplementation with a multispecies probiotic (1 g per day)
Study: 21632815
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg, single sc injection)
Study: 18823693
Drug: Immediate endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Study: 18823693
Drug: Delayed endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Study: 18823693
Drug: Delayed endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed endocrine treatment (ET)
Study: 18823693
Drug: Immediate endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate endocrine treatment (ET)
Study: 17167925
Drug: Other protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other protease inhibitors
Study: 14516301
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention with monthly audit sessions and outcome feedback for malaria treatment.
Study: 14516301
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention with monthly audit sessions and outcome feedback for diarrhoea treatment.
Study: 14516301
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention with monthly audit sessions and outcome feedback for pneumonia treatment.
Study: 11079651
Drug: Orbufiban 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbufiban 30 mg, 40 mg, or 50 mg twice daily or 50 mg once daily
Study: 8932852
Drug: Hib-diphtheria toxoid
Normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 6 months and pneumococcal polysaccharide vaccine (Pnc PS) at 8 months
Study: 8932852
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (Pnc PS) at 18 months and Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 20 months
Study: 1446399
Drug: Propofol 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.3 mg/kgr
Study: 1446399
Drug: Thiopental 4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 4.4 mg/kgr
Study: 3997307
Drug: Carbamazepine tablets
Normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine tablets with rapid absorption
Study: 3997307
Drug: Carbamazepine tablets
Normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine tablets with slow absorption
Study: 3997307
Drug: All carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All carbamazepine tablets
Study: 29370819
Drug: FF/VI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI + UMEC 100/25 μg + 62.5 μg
Study: 24828020
Drug: RO-151 200
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-151 200 mg
Study: 24828020
Drug: RO-838 200
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-838 200 mg
Study: 24828020
Drug: RO-151 5
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-151 5 mg
Study: 24828020
Drug: RO-838 50
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO-838 50 mg
Study: 18757193
Drug: Increasing maximum
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increasing maximum whole breast irradiation (WBI) dose
Study: 10065579
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg orally
Study: 7307478
Drug: Holistic health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic health therapy plus family therapy for 10 weeks
Study: 29627312
Drug: Heliox (79:21)
Normalized name: Helixate
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heliox (79:21) delivered via low flow nasal cannula at 2 L/min for 24 hours
Study: 29627312
Drug: Air delivered
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air delivered via nasal cannula at 2 L/min for 24 hours
Study: 28634710
Drug: Vuse Solo
Normalized name: Fallback Solo
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vuse Solo (14 to 36 mg nicotine)
Study: 25370595
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 32 mg/day orally for 7 days
Study: 23163959
Drug: Olopatadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine (5 mg b.i.d.)
Study: 19455296
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (interpersonal psychotherapy plus medication)
Study: 15554350
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg/day for 3 months
Study: 8301447
Drug: Haemophilus capsular
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in a single syringe (group 1)
Study: 8301447
Drug: Haemophilus capsular
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in separate syringes (group 2)
Study: 8301447
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine (group 1)
Study: 8301447
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine (group 2)
Study: 4174488
Drug: Long-term anticoagulant
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term anticoagulant therapy for one year
Study: 4174488
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no long-term anticoagulant therapy)
Study: 31489525
Drug: Biobran/MGN-3 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobran/MGN-3 (250 mg/day for 3 months)
Study: 24858657
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (nitrate content 7.5 mmol per 250 ml)
Study: 24858657
Drug: Placebo (nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nitrate depleted beetroot juice, nitrate content 0.002 mmol per 250 ml)
Study: 19056592
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg liquid DHA
Study: 17806025
Drug: Post‐incisional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐incisional wound infiltration with levobupivacaine 1.25 mg/kg
Study: 17806025
Drug: Paracetamol 30
Normalized name: Paracetamol 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 30 mg/kg administered rectally
Study: 11094004
Drug: Ketamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (25 mg/24 h)
Study: 27660289
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein treatment
Study: 27660289
Drug: Zinc, selenium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc, selenium, glutamine, and metoclopramide treatment
Study: 19135567
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg of EE and 150 mcg of desogestrel (DSG) for 6 months
Study: 19135567
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg of EE and 2 mg of chlormadinone acetate (CMA) for 6 months
Study: 19135567
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (EE/DSG and EE/CMA)
Study: 17386385
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of technetium 99m sestamibi at 30 to 60 minutes after balloon inflation (group 1, n = 20)
Study: 17386385
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of technetium 99m sestamibi at 90 to 120 minutes after balloon inflation (group 2, n = 10)
Study: 8989332
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single intramuscular dose, maximum dose of 50 mg/kg)
Study: 8989332
Drug: Trimethoprim-sulfamethoxazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (10 days of oral treatment, 8 mg of TMP and 40 mg of SMZ/kg/day in two divided doses)
Study: 23849005
Drug: Community pharmacist's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacist's intervention (drug dosing adjustment service)
Study: 16670361
Drug: 5‐HT3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT3 receptor antagonist (5‐HT3RA) plus dexamethasone
Study: 16670361
Drug: 5‐HT3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT3 receptor antagonist (5‐HT3RA)
Study: 12005142
Drug: Astra Tech
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra Tech implants
Study: 10437252
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) drugs for supporting healthy energy and removing blood stasis
Study: 3061846
Drug: Lymecycline therapy
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline therapy (300 mg b.i.d. for 14 days)
Study: 3061846
Drug: Lymecycline therapy
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline therapy
Study: 3061846
Drug: Lymecycline therapy
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline therapy and Placebo
Study: 16526560
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg TLP (Talampanel) administered orally in fasted and fed states.
Study: 12517808
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/m2)
Study: 12517808
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg/m2)
Study: 10644869
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination after one dose of GM-CSF (24 hours post-administration)
Study: 10644869
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of hepatitis B vaccine after one dose of GM-CSF (24 hours post-administration)
Study: 10644869
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of hepatitis B vaccine alone (control for booster dose)
Study: 2252161
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (IT) with an alginate-conjugated extract of D. pteronyssinus
Study: 6794308
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin daily for 6 weeks
Study: 28401794
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine (1850 MBq)
Study: 28401794
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (3700 MBq)
Study: 24360978
Drug: High-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose soy isoflavone (300 mg/day)
Study: 9573762
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg daily for 5 days a week)
Study: 29464504
Drug: 2 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/h of propofol (P2)
Study: 29464504
Drug: 1 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/h of propofol (P1)
Study: 29464504
Drug: 0.5 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/h of propofol (P0.5)
Study: 24424711
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg rimonabant
Study: 22754096
Drug: succinylcholine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine (1.0 mg/kg BW)
Study: 22754096
Drug: rocuronium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium (0.5 mg/kg BW)
Study: 22754096
Drug: saline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (15 mL)
Study: 19924124
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (300 mg t.i.d.)
Study: 19924124
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg b.i.d.)
Study: 18515308
Drug: Daily orally
Normalized name: Daily Hist Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily orally administered calcitriol
Study: 18515308
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and intravenous calcitriol)
Study: 8843129
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (first half of therapy)
Study: 8843129
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements (second half of therapy)
Study: 1609035
Drug: Buprenorphine (1.5-8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (1.5-8.0 mg/day)